[Emerging therapies for inflammatory rheumatic diseases]

Rheumatologists face daily challenges in managing inflammatory rheumatic diseases (rheumatoid arthritis, axial spondylarthritis, and psoriatic arthritis). Significant advancements in our therapeutic arsenal have occurred over the past decades. However, achieving remission remains an unattainable goal for many patients, highlighting the need for new treatment options. This article summarizes findings presented at recent European and American rheumatology congresses, focusing on current practice evaluations, new drugs and therapeutic classes, and innovative uses of existing medications, including residual level monitoring.